YPB makes concerted push into China with two new contracts

|

Published 27-AUG-2020 10:16 A.M.

|

5 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Product authentication and consumer engagement solutions provider YPB Group Limited’s (ASX:YPB) China business is sustaining its improved new momentum with two important new channel partners.

The first is a high-volume pharmaceutical packaging supplier, effectively marking YPB’s entry into the pharmaceutical sector.

The second is a well-established label printer with a broad, blue-chip customer base.

In the first year, the two contracts together are expected to add around $75,000 in revenue with possible upside in years two and three as YPB’s solutions are on-sold to the channel partners’ end customers.

By way of background, YPB's proprietary Brand Protection and Consumer Engagement suite allows Government and Brands to protect their assets and their consumers to confirm product authenticity; for brands it can trigger consumer engagement.

The combination of YPB’s smartphone authentication solutions and its SaaS Connect platform creates ‘smart’ product packaging, opening cost-effective, digital and direct marketing channels between brands and their consumers.

Three-year contract with packaging group

YPB China has signed a three-year contract to supply Suzhou-Haishun Packaging Material Co. Ltd with YPB’s proven T2 tracer-scanner authentication solution.

In a unique product innovation, Suzhou-Haishun will incorporate YPB tracer into an advanced foil application for a pharmaceutical customer in China with a YPB T2 scanner used to confirm product authenticity through the supply chain.

YPB will supply its proprietary tracer and scanners with minimum annual take or pay conditions, and with additional incentives for increased volume.

Suzhou-Haishun will promote the brand and consumer protection benefits of YPB’s solutions more broadly to its customers, and management anticipates growth beyond the contracted minimum value over time.

Suzhou-Haishun Group is a prominent, large pharmaceutical packaging and flexible packaging material (laminated foil and end products) manufacturer in China, producing cold-forming foils, tropical blister foils, suppository films plus lid stock of all types for pharmaceutical, cosmetic and food applications.

The group has a portfolio of major clients domestically and globally and is certified by the US FDA and DMF (Drug Master File).

The contract has a minimum total contract value of A$75,000. Further information about the contracts can be read in YPBs ASX release and on the YPB website ypb.io.

Three-year contract with Beijing Haihui Printing

A second 3-year supply contract has been signed with Beijing Haihui Printing Co. Ltd which will integrate YPB’s product authentication tracer and scanner technology into anti-counterfeiting label printing for its customers.

Haihui is a well-established printing company that has been operating in China for over 20 years delivering integrated planning, design, production, printing and packaging.

The group specialises in the technical research and development, design and printing services of self-adhesive label identification, anti-counterfeiting label identification and various composite label identification.

Haihui provides labelling services for nearly 100 customers across a diverse range of sectors, and its customers include Nippon Coatings, CQC, Sinopec, ZFT, Duoduo Pharmaceutical, Tsinghua Unigroup, Sony Ericsson and French Andros.

Revenues will be based on purchase orders.

Commenting on the significance of these developments, particularly in light of the company’s revised sales strategy in China, YPB chief executive John Houston, “Securing two new, high quality China channel partners in new end-customer segments that are immediately revenue generating and with the sales process occurring through the difficulties of COVID-19 reflects the increasing effectiveness of our revised China sales strategy.

“Over the past ten months, YPB China has developed new channel partnerships in a number of large and lucrative sectors.

“We are now better at demonstrating the value, relevance and simplicity of our forensic tracer-scanner solution.

“The fact that major intermediaries are staking their own reputations by offering YPB’s solutions to secure product authenticity for their customers’ products is proving that there is indeed a significant market for high quality anti-counterfeit solutions.

“We’ve always had great technology, and after years of toiling we are now creating an effective sales machine.”

Indeed, YPB is steadily building a base of longer-term contracts and with strong client management the group can generate repeat orders and recurring revenues.

Despite market conditions YPB’s China operations have continued to adapt and improve by better contract management and increasing the incidence of “take or pay” provisions.

The potential to generate additional revenue streams in China is enormous, and YPB’s growing suite of channel partners provides leveraged market access to those very high volumes.

Sound channel management is expected to result in revenue growth and ultimately a profitable China business over time.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X